Explore how Dextramer® reagents support the development of effective cell therapies.
CAR Dextramer® for Rapid Detection and Characterization of CAR Cells
CAR Dextramer®
CAR T cell therapy has transformed cancer immunotherapy by enabling targeting of disease-specific antigens such as CD19, BCMA, and mesothelin (MSLN). Accurate detection of CAR-expressing cells is essential for both therapy development and monitoring.
By multimerizing high-quality antigen proteins and fluorochrome molecules, CAR Dextramer® reagents provide a rapid, easy-to-use solution for CAR cell detection.
Read the Blog: “Avidity can make all the difference in detecting CAR-engineered cells”.
Read more
Catalog Number |
Product Name/Description |
Test Size |
Dye |
| CT001 | CAR Dextramer®, CD19, human | 50 tests | PE |
|
CT003 |
CAR Dextramer®, BCMA, human |
50 tests |
PE |
|
CT006 |
CAR Dextramer®, MSLN, human |
50 tests |
PE |
Streamlined Workflow with CAR Dextramer®
Experience a faster, more efficient process with quick staining and direct detection of CAR cells. CAR Dextramer® reagents provide precise confirmation of receptor expression and directly verify the CAR's ability to recognize its target antigen.
Primary human CD19 CAR-T cells stained with PE-labelled CAR Dextramer® CD19. Control Dextramer® was used as negative control.
Want to see more results?
Our collaborators have compared CAR Dextramer® reagents with alternative CAR detection methods across different constructs and expression levels.
CAR Dextramer® reagents enable:
- Reliable detection across different CAR constructs
- Direct antigen-based detection without reliance on tags
- A simplified workflow with fewer staining steps
Dive into the performance data in this blog post.
View performance data
Enhanced CAR Cell Detection with Dextramer® Technology
- Optimized Reagent Design: Backed by over a decade of expertise in immune monitoring, our reagents are designed for robust detection performance
- Antigen-Based Reagent: Directly demonstrates the CAR’s ability to bind its target antigen, verifying receptor functionality
- Reliable Results: Provides consistent, high-quality results across experiments
- Simplified Staining Protocol: Easy one-step staining at room temperature with minimal wash steps
- Simultaneous phenotyping: Enables detection of CAR T cells alongside key surface markers such as CCR7 and CD45
Applications of CAR Dextramer® in CAR Cell Therapy
- Direct CAR cell detection
- Demonstrate that the CAR binds to its target antigen
- Determine the % of CAR-positive cells
- Demonstrate that the infusion product meets defined release criteria
- Monitor kinetics and persistence of CAR cells in patient samples
- Characterize target-specific CAR cells using gene and surface marker analysis
FDA Guidance for CAR-T cell Therapy Products
The most recent guidance from the FDA regarding the development of CAR cell products includes recommendations for detecting and evaluating the CAR product.
Dextramer® reagents can assist you in adhering to this guidance.
or
Dextramer® Controls
We recommend using negative controls with CAR Dextramer® reagents to accurately distinguish between background and antigen-specific staining, helping you optimize gating or sorting of positive cells.
One possible negative control Dextramer® reagent can be found here. Alternatively, we are happy to discuss other negative controls with you, or create a custom solution for you.
Related Resources
CAR Therapy Brochure
Learn how CAR Dextramer® enables superior detection and characterization of CAR cells.